Corrigendum to “A novel mechanism of inhibiting in-stent restenosis with arsenic trioxide drug-eluting stent: Enhancing contractile phenotype of vascular smooth muscle cells via YAP pathway” [Bioact. Mater. 6 2 (February 2021) 375–385]
Guardado en:
Autores principales: | Yinping Zhao, Guangchao Zang, Tieying Yin, Xiaoyi Ma, Lifeng Zhou, Lingjuan Wu, Richard Daniel, Yunbing Wang, Juhui Qiu, Guixue Wang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
KeAi Communications Co., Ltd.
2022
|
Materias: | |
Acceso en línea: | https://doaj.org/article/bb77338c2dd04ec89e5d187f0a5c2725 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Long-term outcomes after treatment of in-stent restenosis using the Absorb everolimus-eluting bioresorbable scaffold
por: Stefan Toggweiler, et al.
Publicado: (2021) -
Comparison of Drug-Coated Balloon Angioplasty vs. Drug-Eluting Stent Implantation for Drug-Eluting Stent Restenosis in the Routine Clinical Practice: A Meta-Analysis of Randomized Controlled Trials
por: Yong Zhu, et al.
Publicado: (2021) -
Everolimus-eluting coronary stents
por: Alejandro Saez, et al.
Publicado: (2010) -
Factors affecting in-stent restenosis after angioplasty with the Enterprise stent for intracranial atherosclerotic diseases
por: Kun Zhang, et al.
Publicado: (2021) -
Pathogenesis and Clinical Significance of In-Stent Restenosis in Patients with Diabetes
por: Grzegorz K. Jakubiak, et al.
Publicado: (2021)